Advanced Pancreatic Cancer: A Phase I-II Trial of Cisplatin, High-Dose Cytarabine, and Caffeine
- 15 November 1989
- journal article
- research article
- Published by Oxford University Press (OUP) in JNCI Journal of the National Cancer Institute
- Vol. 81 (22), 1735-1738
- https://doi.org/10.1093/jnci/81.22.1735
Abstract
In a phase I-II study, 28 patients with advanced pancreatic adenocarcinoma were treated with cisplatin, highdose cytarabine (ARA-C), and caffeine. This clinical trial was based on a nude mouse-human tumor xenograft model, which demonstrated synergism of these agents by inhibiting the growth of human pancreatic tumors. Toxic effects noted in the clinical study included myelosuppression, moderate nausea and vomiting, and mild renal insufficiency. No toxic effects were directly attributable to caffeine. Eighteen of the 28 patients had measurable or assessable disease; seven (39%) had partial responses (95% confidence intervals, 18%–63%). The median response duration was 6.2 months. Median survival for responders was 9.5 months with two patients surviving for more than 18 months. Median survival for all patients was 6.1 months. The combination of cisplatin, ARA-C, and caffeine is an active and tolerable regimen in the treatment of advanced pancreatic cancer. A phase III trial in which this regimen is being compared with standard therapy is in progress. [J Natl Cancer Inst 81:1735–1738, 1989]This publication has 11 references indexed in Scilit:
- REDUCTION BY CAFFEINE OF ADRIAMYCIN-INDUCED CELL KILLING AND DNA DAMAGE IN CHINESE-HAMSTER CELLS - CORRELATION WITH MODULATION IN INTRACELLULAR ADRIAMYCIN CONTENT1987
- Chemotherapy for advanced pancreatic cancer.A comparison of 5-fluorouracil, adriamycin, and mitomycin (fam) with 5-fluorouracil, streptozotocin, and mitomycin (fsm)Cancer, 1986
- ENHANCED THERAPEUTIC EFFECT OF CIS-DIAMMINEDICHLOROPLATINUM(II) AGAINST NUDE-MOUSE GROWN HUMAN PANCREATIC ADENOCARCINOMA WHEN COMBINED WITH 1-BETA-D-ARABINOFURANOSYLCYTOSINE AND CAFFEINE1985
- Phase II evaluation of dihydroxyanthracenedione (DHAD, NSC 301739) in patients with upper gastrointestinal tumorsAmerican Journal of Clinical Oncology, 1983
- Phase II evaluation of m-AMSA (4'-(9-acridinylamino)-methane-sulfon-m-anisidide) in patients with adenocarcinoma of the pancreasAmerican Journal of Clinical Oncology, 1983
- Mice, men, mustards and methylated xanthines: the potential role of caffeine and related drugs in the sensitization of human tumours to alkylating agentsBritish Journal of Cancer, 1981
- 5-Fluorouracil, adriamycin, and mitomycin-C (FAM) chemotherapy for advanced adenocarcinoma of the pancreasCancer, 1980
- RANDOMIZED TRIAL OF CHLORPROMAZINE, CAFFEINE, AND METHYL-CCNU IN DISSEMINATED MELANOMA1980
- Phase II trial of streptozotocin, mitomycin-C and 5-fluorouracil (SMF) in the treatment of advanced pancreatic cancerCancer, 1978
- High dose Cis-platinum diammine dichloride.Amelioration of renal toxicity by mannitol diuresisCancer, 1977